The sensitivity of METex14 skipped patients to MET inhibitors has resulted in several case reports of dramatic responses in the literature [6,7], and various clinical trials of MET tyrosine kinase inhibitors in METex14 mutated NSCLC are consequently currently ongoing [4]. Here, MET is linked to non-small cell lung carcinoma.